Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Operating Leases (2021 - 2025)

iBio (IBIO) has disclosed Operating Leases for 5 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 21.14% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 21.14% decrease, with the full-year FY2025 number at $2.2 million, down 18.19% from a year prior.
  • Operating Leases was $1.9 million for Q4 2025 at iBio, down from $2.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.5 million in Q1 2022 to a low of $1.9 million in Q4 2025.
  • A 5-year average of $3.1 million and a median of $3.0 million in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: decreased 1.01% in 2022, then crashed 41.87% in 2023.
  • iBio's Operating Leases stood at $5.4 million in 2021, then plummeted by 38.44% to $3.3 million in 2022, then fell by 12.39% to $2.9 million in 2023, then dropped by 15.87% to $2.4 million in 2024, then fell by 21.14% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Operating Leases are $1.9 million (Q4 2025), $2.1 million (Q3 2025), and $2.2 million (Q2 2025).